Title: The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Journal: Antimicrobial agents and chemotherapy 20140601
Title: Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.
Journal: Antimicrobial agents and chemotherapy 20140501
Title: Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
Journal: Hepatology (Baltimore, Md.) 20140201
Title: Tetrazole and triazole as bioisosteres of carboxylic acid: discovery of diketo tetrazoles and diketo triazoles as anti-HCV agents.
Journal: Bioorganic & medicinal chemistry letters 20130815
Title: Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Journal: Hepatology (Baltimore, Md.) 20120401
Title: Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Journal: Gastroenterology 20120401
Title: Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.
Journal: Antiviral therapy 20120101
Title: The HCV NS5B nucleoside and non-nucleoside inhibitors.
Journal: Clinics in liver disease 20110801
Title: RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Journal: The Journal of infectious diseases 20101115
Title: Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor.
Journal: Journal of pharmaceutical and biomedical analysis 20101102
Title: Management of untreated and nonresponder patients with chronic hepatitis C.
Journal: Seminars in liver disease 20101101
Title: Curing hepatitis C with pills: a step toward global control.
Journal: Lancet (London, England) 20101030
Title: Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Journal: Lancet (London, England) 20101030
Title: Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
Journal: Journal of medicinal chemistry 20101014
Title: Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
Journal: Journal of medicinal chemistry 20090910
Title: Le Pogam S, et al. Characterization of HCV quasispecies dynamics upon short term dual-therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob Agents Chemother. 2012 Nov;56(11):5494-5
Title: Soriano V, et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother. 2011 Aug;66(8):1673-86
Title: Guedj J, et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology. 2012 Apr;55(4):1030-7.
